Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus Relatlimab or Ipilimumab in Metastatic Melanoma
NCT03724968Phase 2Terminated
- Start
- Jan 2019
- Primary completion
- May 2020
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of relatlimab in melanoma. Started Jan 2019; status: terminated.
02
Drugs
relatlimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03724968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03724968.